Abstract
This year marks the 50th anniversary of the discovery of the psychological effects of Lysergic Acid Diethylamide (LSD) by Albert Hofmann in the Swiss laboratories of the Sandoz pharmaceutical company. It also marks a resurgence of interest around the world in the possible medical applications of psychedelic and related drugs in treating psychiatric illness. The fate of psychedelic drugs in psychiatry [1] represents a curious chapter in our history and cannot be separated from the socio-political context of the mid to late 1960's, particularly in the United States [2]. Certainly psychedelic assisted therapies were not a passing fad. “Between 1950 and the mid-1960s there were more than a thousand clinical papers discussing 40,000 patients, several dozen books, and six international conferences on psychedelic drug therapy” [1]. What is evident is that research into psychedelic assisted therapies did not cease because these drugs were proven ineffective. On the contrary, in 1966 when Sandoz withdrew LSD from ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
